Different legal orders have taken varying approaches to regulating the collection, analysis and sharing of personally identifiable health data and to defining requirements for rendering health data anonymous. This topic is of great importance for hospitals, pharmaceutical companies, and medical device manufacturers. It is also raised by developments in the “internet of medical things.” This session will consider how organizations can develop and deploy innovative products and services, while complying with sometimes competing demands for the use of anonymous or pseudonymous health data in EU, Swiss, and U.S. law.
Thomas Steiner, Head, Data & Privacy Practice, Vischer AG (Zürich)
Elizabeth Canter, Partner, Covington & Burling LLP
Jennifer Chillas, Senior Corporate Counsel, Bristol-Myers Squibb
Are Pseudonymous Data Always Personal Data: Implications of the GDPR for Administrative Data Research in the UK_Miranda Mourby, Elaine Mackey, Mark Elliot, Heather Gowans, Susan Wallace, Jessica Bell, Hannah Smith, Stergios Aidinlis, Jane Kaye
Bloomberg BNA: Privacy and Security Law Report, Paul Schwartz, Daniel Solove